Pathogenetic rationale for prescribing menopausal hormone therapy for systemic sclerosis
Systemic scleroderma (SS) is characterized by dysregulation of the innate and adaptive immune systems, vasculopathy, and generalized fibrosis. As with most autoimmune diseases, women predominate among patients, who get sick 3–14 times more often than men. It is assumed that gender differences and mo...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2022-11-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/3220 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849400963072262144 |
|---|---|
| author | T. S. Panevin L. P. Ananyeva |
| author_facet | T. S. Panevin L. P. Ananyeva |
| author_sort | T. S. Panevin |
| collection | DOAJ |
| description | Systemic scleroderma (SS) is characterized by dysregulation of the innate and adaptive immune systems, vasculopathy, and generalized fibrosis. As with most autoimmune diseases, women predominate among patients, who get sick 3–14 times more often than men. It is assumed that gender differences and modulation of sex hormones are essential in the pathogenesis of SS. Estrogens are able to influence the immune response, have a vasodilating effect and stimulate the synthesis of collagen in the skin. The development of SS leads to a significant decrease in the quality of life, psychological disorders associated with changes in appearance, as well as the need for lifelong medication with the frequent development of side effects. Age-related estrogen deficiency associated with the onset of menopause is accompanied by a decrease in the quality of life and, in some cases, a change in the clinical manifestations of somatic diseases. This review considers the impact of menopause and menopausal hormone therapy (MHT) on the course and clinical manifestations of systemic scleroderma. It is noted that SS in some cases is accompanied by an early onset of menopause. The use of MHT is not associated with the progression of cutaneous fibrosis, and may also improve the vascular manifestations of SS. |
| format | Article |
| id | doaj-art-63d3887f6fda4369ae3670d0d3216512 |
| institution | Kabale University |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2022-11-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-63d3887f6fda4369ae3670d0d32165122025-08-20T03:37:53ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922022-11-0160553854510.47360/1995-4484-2022-538-5452841Pathogenetic rationale for prescribing menopausal hormone therapy for systemic sclerosisT. S. Panevin0L. P. Ananyeva1V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologySystemic scleroderma (SS) is characterized by dysregulation of the innate and adaptive immune systems, vasculopathy, and generalized fibrosis. As with most autoimmune diseases, women predominate among patients, who get sick 3–14 times more often than men. It is assumed that gender differences and modulation of sex hormones are essential in the pathogenesis of SS. Estrogens are able to influence the immune response, have a vasodilating effect and stimulate the synthesis of collagen in the skin. The development of SS leads to a significant decrease in the quality of life, psychological disorders associated with changes in appearance, as well as the need for lifelong medication with the frequent development of side effects. Age-related estrogen deficiency associated with the onset of menopause is accompanied by a decrease in the quality of life and, in some cases, a change in the clinical manifestations of somatic diseases. This review considers the impact of menopause and menopausal hormone therapy (MHT) on the course and clinical manifestations of systemic scleroderma. It is noted that SS in some cases is accompanied by an early onset of menopause. The use of MHT is not associated with the progression of cutaneous fibrosis, and may also improve the vascular manifestations of SS.https://rsp.mediar-press.net/rsp/article/view/3220systemic sclerosisraynaud’s phenomenonpulmonary hypertensionestrogensmenopausemenopausal hormone therapy |
| spellingShingle | T. S. Panevin L. P. Ananyeva Pathogenetic rationale for prescribing menopausal hormone therapy for systemic sclerosis Научно-практическая ревматология systemic sclerosis raynaud’s phenomenon pulmonary hypertension estrogens menopause menopausal hormone therapy |
| title | Pathogenetic rationale for prescribing menopausal hormone therapy for systemic sclerosis |
| title_full | Pathogenetic rationale for prescribing menopausal hormone therapy for systemic sclerosis |
| title_fullStr | Pathogenetic rationale for prescribing menopausal hormone therapy for systemic sclerosis |
| title_full_unstemmed | Pathogenetic rationale for prescribing menopausal hormone therapy for systemic sclerosis |
| title_short | Pathogenetic rationale for prescribing menopausal hormone therapy for systemic sclerosis |
| title_sort | pathogenetic rationale for prescribing menopausal hormone therapy for systemic sclerosis |
| topic | systemic sclerosis raynaud’s phenomenon pulmonary hypertension estrogens menopause menopausal hormone therapy |
| url | https://rsp.mediar-press.net/rsp/article/view/3220 |
| work_keys_str_mv | AT tspanevin pathogeneticrationaleforprescribingmenopausalhormonetherapyforsystemicsclerosis AT lpananyeva pathogeneticrationaleforprescribingmenopausalhormonetherapyforsystemicsclerosis |